DMAC (DiaMedica Therapeutics) Marketable Securities: $46.46 Mil (As of Mar. 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.45
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Marketable Securities?

DiaMedica Therapeutics DMAC +5.53% 31 Marketable Securities is $46.46 Mil as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. DiaMedica Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $46.46 Mil.

DiaMedica Therapeutics's annual Marketable Securities declined from Dec. 2023 ($48.35 Mil) to Dec. 2024 ($41.12 Mil) but then increased from Dec. 2024 ($41.12 Mil) to Dec. 2025 ($44.24 Mil).

DiaMedica Therapeutics  (NAS:DMAC) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

DiaMedica Therapeutics Marketable Securities Related Terms

DiaMedica Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Marketable Securities Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.41 28.77 48.35 41.12 44.24

DiaMedica Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.73 25.93 51.99 44.24 46.46
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $46.46 Mil mean?
DiaMedica Therapeutics (DMAC) has a Marketable Securities of $46.46 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Marketable Securities too high?
DiaMedica Therapeutics' current Marketable Securities is $46.46 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Marketable Securities compare to PRLD and RCKT?
DiaMedica Therapeutics' Marketable Securities of $46.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Marketable Securities is $46.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Marketable Securities of $46.46 Mil. The current Marketable Securities is $46.46 Mil. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Marketable Securities is $46.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price